# US 2015/0104385 A1 · Radio-pharmaceutical complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104385 A1
- Document ID: US20150104385A1
- Status: Published application
- Kind: A1
- Application number: 14/400,020
- Filed: 2013-05-13
- Published: 2015-04-16
- Earliest claimed: 2012-05-11
- Assignees: Algeta ASA
- Applicants: Algeta ASA
- Inventors: Hanne Therese Bonge-Hansen; Olav Benjamin Ryan
- Web page: https://patentgrep.com/patent/US20150104385A1

## CPC

- A61K 51/0474: {complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.

## Claims

### Claim 1

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor.

### Claim 2 (depends on 1)

The complex as claimed in claim 1 comprising at least one 3,2-HOPO moiety.

### Claim 3 (depends on 1, 2)

The complex as claimed in claim 1 or claim 2 wherein all 4 HOPO moieties comprise hydroxyalkyl solubilising moieties at the N-position.

### Claim 4 (depends on 1, 2)

The complex as claimed in claim 1 or claim 2 comprising an octadentate ligand comprising four chelating moieties of formula I
Wherein R1 is an optional N-substituent solubilising group which will be present in at least one of the four moieties of formula I; groups R2 to R6 are each independently selected from H, OH, ═O, short hydrocarbyl groups, linker moieties and/or coupling moieties wherein one of R2 to R6 is OH and one of R2 to R6 is ═O.

### Claim 5 (depends on 4)

The complex as claimed in claim 4 wherein at least one of groups R1 to R6 is a linker moiety.

### Claim 6 (depends on 4, 5)

The complex as claimed in any of claims 4 to 5 comprising four 3,2-hydroxypyridinone moieties.

### Claim 7

The complex as claimed in any preceding claim wherein the N-substituents on each of the four HOPO groups are each independently chosen from HO—, HOCH2—, HOCH2CH2—, HO—CH2CH2CH2—, HO—CH(CH3)CH2—, HO—CH2CH2CH2CH2—, HO—CH(CH3)CH2CH2—, HO—CH(CH2CH3)CH2—, HO—C(CH3)2CH2—, HO—CH(CH3)CH(CH3)— and HOCH2CH(CH2CH3)—.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The complex as claimed in any of claims 1 to 7, wherein said ion of an alpha-emitting thorium radionuclide is the 4+ ion of an alpha-emitting thorium radionuclide such as 227Th.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A complex as claimed in any of claims 1 to 8 comprising a ligand moiety of formula VI:
Wherein RL is any suitable linker moiety.

### Claim 10

A complex as claimed in any preceding claim wherein the tissue targeting moiety is a monoclonal or polyclonal antibody, an antibody fragment (such as Fab, F(ab′)2, Fab′ or scFv), or a construct of such antibodies and/or fragments.

### Claim 11

A complex as claimed in any preceding claim wherein the tissue targeting moiety comprises at least one peptide chain having at least 90% sequence similarity with at least one of the following sequences:
Light Chain:
(Seq ID 1)
DIQLTQSPSSLAVSAGENVTMSCKSSQSVLYSANHKNYLAWYQQKPGQS
PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVQVEDLAIYYCHQYL
SSWTFGGGTKLEIKR
(Seq ID 2)
DIQLTQSPSSLASAAVEDRTMSCKSSQSVLYSANHKNYLAWYQQKPGQK
AKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYL
SSWTFGGGTKLEIKR
Heavy Chain:
(Seq ID 3)
QVQLQESGAELSKPGASVKMSCKASGYTFTSYWLHWIKQRPGQGLEWIG
YINPRNDYTEYNQNFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCAR
RDITTFYWGQGTTLTVSS
(Seq ID 4)
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIG
YINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCAR
RDITTFYWGQGTTVTVSS
(Seq ID 5)
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIG
YINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCAR
RDITTFYWGQGTTVTVSS

### Claim 12

Use of a tissue targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor, in the manufacture of a medicament for the treatment of hyperplastic or neoplastic disease.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use as claimed in claim 12 wherein said tissue-targeting complex is a complex as claimed in any of claims 1 to 11.

### Claim 14 (depends on 12, 13)

Use as claimed in claim 12 or claim 13 wherein said disease is a carcinoma, sarcoma, myeloma, leukemia, lymphoma or mixed type cancer including Non-Hodgkin's Lymphoma or B-cell neoplasms.

### Claim 15

A method of treatment of a human or non-human animal (particularly one in need thereof) comprising administration of at least one tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group wherein the tissue targeting moiety has binding affinity for the CD22 receptor.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15)

The method of claim 15 wherein said tissue-targeting complex is a complex as claimed in any of claims 1 to 11.

### Claim 17 (depends on 15, 16)

The method as claimed in claim 15 or claim 16 for the treatment of hyperplastic or neoplastic disease, such as a carcinoma, sarcoma, myeloma, leukemia, lymphoma or mixed type cancer, including Non-Hodgkin's Lymphoma or B-cell neoplasms.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A tissue targeting complex as claimed in any of claims 1 to 11 for use in therapy.

### Claim 19 (depends on 18)

A tissue targeting complex as claimed in claim 18 for use in the treatment of hyperplastic and/or neoplastic disease such as a carcinoma, sarcoma, myeloma, leukemia, lymphoma or mixed type cancer including Non-Hodgkin's Lymphoma or B-cell neoplasms.

### Claim 20

A pharmaceutical composition comprising a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group wherein the tissue targeting moiety has binding affinity for the CD22 receptor, together with at least one pharmaceutical carrier or excipient.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20)

The pharmaceutical composition as claimed in claim 20 comprising a tissue-targeting complex is a complex as claimed in any of claims 1 to 11.

### Claim 22 (depends on 15, 16, 17)

A kit for use in a method according to any of claims 15 to 17, said kit comprising a tissue targeting moiety, conjugated or conjugatable to an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor, said kit optionally and preferably include an alpha-emitting thorium radionuclide, such as 227Th.

### Claim 23

A method of formation of a tissue-targeting complex, said method comprising coupling a tissue targeting moiety to an octadentate hydroxypyridinone-containing ligand in aqueous solution, the complex comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor.

### Claim 24 (depends on 23)

The method of claim 23 comprising preparing a first aqueous solution of octadentate hydroxypyridinone-containing ligand and a second aqueous solution of said tissue targeting moiety and contacting said first and said second aqueous solutions.

### Claim 25 (depends on 24)

The method of claim 24 wherein said contacting is conducted at below 40° C.

### Claim 26 (depends on 24, 25)

The method of claim 24 or claim 25 wherein said contacting is conducted in the substantial absence of any organic solvent.

### Claim 27 (depends on 23, 24, 25, 26)

The method of any of claims 23 to 26 wherein said coupling yields an amide, ester, ether or amine bond between the chelate and the antibody.

### Claim 28 (depends on 27)

The method of claim 27 wherein said ester or amide linkage is formed by means of at least one activated ester group, for example formed by means of at least one N-hydroxy maleimide, carbodiimide or azodicarboxylate coupling reagent.
